Loading
A phase 1/2 trial of Tislelizumab, Bevacizumab in hepatocellular carcinoma and non-small-cell lung cancer, run by BeOne Medicines, now recruiting.
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06427941 by BeOne Medicines, with 630 participants planned, started 2024-07-23 and due to reach its primary completion in 2027-03-31. Interventions recorded: BGB-B2033, Tislelizumab, Bevacizumab. Conditions listed: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Hepatocellular carcinoma, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.